Understanding Resistant to CAR-T Immunotherapy to Develop Better Next-generation Therapies

May 4 2022

CAR T therapy is changing the treatment paradigm for lymphoid malignancies. However, there are still significant challenges to be overcome as the majority of patients will eventually fail this therapy. Moreover, CAR T therapy is still not working satisfactorily in most cancer types. Dr. Ruella will provide an overview of the latest findings of his group on resistance mechanisms to CAR T immunotherapy, including the use of next-generation platforms such as single-cell RNA sequencing and functional genomics to design novel effective therapies.

The format is the following:

5 mins – introduction
20 mins – main discussion
20 min+ – Q&A

Watch the webinar here: https://youtu.be/3VYZo8VfOdk

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets.

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Meet Scailyte at BioTechX

Meet Scailyte at BioTechX at Booth #37 in Basel Congress Center from 8th to 10th November 2022.

Scailyte closes Series A funding with a CHF 6 million investment

Scailyte has successfully finished the Series A funding raising CHF 6 million from a Swiss family of

VACANCY: Internship in Women’s Health R&D

The internship in Women’s Health R&D will focus on our in vitro diagnostics development work in en

Nilogen and Scailyte Are Joining Forces to Find the “Right” Treatment for Every Patient

Nilogen and Scailyte are joining forces to increase the success of cancer therapies in clinics and t

Machine learning meets multi-omics for precision medicine

Bringing industry and academia together to discuss the potential impact of single-cell analytics pow